GA-VENTIV-TECHNOLOGY
21.7.2022 11:02:06 CEST | Business Wire | Press release
Ventiv Technology, the leading provider of risk, insurance and underwriting solutions, announced today its inclusion in the Management des Risques et des Assurances de l’Entreprise’s (AMRAE) 2022 Panorama report as leaders in Analytics and Insurance. The association’s 14th annual market analysis is based on vendor and risk manager questionnaires. Among the 55 vendors evaluated, Ventiv was one of only four to be recognized as a leader in the artificial intelligence quadrant, having both functional and technical coverage. Ventiv was one of five vendors to have that same distinction in the insurance quadrant.
According to the report, 63% of risk managers look for one tool to meet all their functional needs, audit, risk management, insurance, internal control, etc., highlighting the growing industry trend towards converging risk management systems that are cross-functional.
“Ventiv continues to grow and expand its offerings to stay on the forefront of tech and innovation,” said Steve Cloutman, Managing Director of Ventiv. “This year's report reinforces known trends and where we are headed as an industry. We look forward to continuing to be a part of moving the industry forward.”
The report also found that ease of use and reporting capabilities are the top two criteria risk managers seek when evaluating a RMIS platform. In addition, the report listed AI as one of the top three functionalities that are on the agenda for future development for most firms.
Ventiv is a differentiator when it comes to its AI-powered data analytics software. Its AI and machine learning algorithms help clients predict outcomes, prioritize time and resources, and improve operational efficiency. Combined with the company’s hands-on customer support and software offerings, clients can easily scale their risk management programs as they grow.
With more than 450 clients across Europe, North America, and Asia, Ventiv provides RMIS solutions to some of the largest global companies across a range of industries, including healthcare, manufacturing, and hospitality. This is the company’s first year being included in the report which was submitted in collaboration with EY.
The AMRAE Panorama Report is an annual publication that presents a global view of RMIS trends, market practices and details on the latest technology in the marketplace. Since 2008 AMRAE has approached the survey with a neutral point of view to provide valuable insights for risk management professionals looking for the latest info on RMIS.
Download the full report or visit Ventiv’s website for more information.
About Ventiv Technology
Ventiv Technology is a leading global provider of risk management information systems (RMIS), enterprise risk management (ERM), insurance claims, billing, policy, and administration technology integrated with its market-leading analytics and predictive models. Ventiv Technology’s SaaS and on-prem solutions are deployed by brokers, insured corporate entities, federal and regional governments, third party claims administrators (TPAs), and risk pools across a variety of industries including transportation & logistics, retail, financial services, leisure & hospitality, carriers & insurers, energy, aviation, manufacturing, government & public entities, and many more.
With over 45 years’ experience, Ventiv proudly boasts over 450 institutions as its customers and more than 350,000 users of Ventiv’s technology in over 40 countries. Ventiv’s global footprint and experienced team of industry veterans delivers insight to organizations that allows our customers to predict, manage, and respond to risk.
For more information, please visit https://www.ventivtech.com or @VentivTech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom